← Back to Search

Antibiotic

Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations (REPRIEVE Trial)

Phase 2
Waitlist Available
Research Sponsored by Aceragen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 7

Summary

This trial is testing a new oral medication called ARV-1801, taken with usual treatment, in cystic fibrosis patients who have lung flare-ups. The medication aims to help clear lung infections and reduce inflammation, improving breathing.

Eligible Conditions
  • CF exacerbation
  • Cystic Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 7
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 7 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Desirability in outcome ranking (DOOR)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ARV-1801(ACG-701) Active GroupActive Control1 Intervention
ARV-1801(ACG-701) tablets by mouth twice a day for 14 days
Group II: Placebo GroupPlacebo Group1 Intervention
Placebo tablets by mouth twice a day for 14 days

Find a Location

Who is running the clinical trial?

AceragenLead Sponsor
1 Previous Clinical Trials
125 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top